Stocks Getting Investor’s Attention: BP p.l.c. (NYSE:BP), Yahoo! Inc. (NASDAQ:YHOO), Pall Corporation (NYSE:PLL), Halozyme Therapeutics, Inc. (NASDAQ:HALO), Alliance One International, Inc. (NYSE:AOI)

BP p.l.c. (NYSE:BP) Chief Executive Bob Dudley told staff in a Monday memo that the company would freeze 2015 base pay, part of a larger round of cost savings and cuts the company has undertaken as oil prices remain at less than half the level of mid-2014, a BP spokesman said. BP p.l.c. (NYSE:BP) belongs to Basic Materials sector. Its net profit margin is 2.50% and weekly performance is 5.44%. On last trading day company shares ended up $39.92. BP p.l.c. (NYSE:BP) distance from 50-day simple moving average (SMA50) is 2.86%.

Yahoo Inc’s (NASDAQ:YHOO) shares are expected to move nearly twice as much as they have following other recent earnings reports when the company announces fourth-quarter results on Tuesday, options data showed. Yahoo! Inc. (NASDAQ:YHOO) shares moved up 1.00% in last trading session and ended the day at $49.44. YHOO Gross Margin is 71.90% and its return on assets is 28.80%. Yahoo! Inc. (NASDAQ:YHOO) quarterly performance is 16.06%.

Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), announced that Orgenesis and Pall Corporation (NYSE:PLL) have received an $800,000 grant from the Israel-U.S. Binational Industrial Research and Development (“BIRD”) Foundation to finance their current $1,600,000 co-development program. On 26 January, Pall Corporation (NYSE:PLL) shares moved up 0.67% and was closed at $101.39. PLL EPS growth in last 5 year was 14.70%. Pall Corporation (NYSE:PLL) year to date (YTD) performance is 0.18%.

On Jan. 12, Halozyme Therapeutics, Inc. (NASDAQ: HALO) provided an update on anticipated 2015 corporate milestones. Present Phase 1b (Study 201) results at ASCO-GI (poster scheduled for January 16, 2015). Complete patient enrollment in the on-going Phase 2 multi-center, randomized clinical trial (Study 202) evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer, in the second half of 2015. Halozyme Therapeutics, Inc. (NASDAQ:HALO) ended the last trading day at $14.44. Company weekly volatility is calculated as 6.24% and price to cash ratio as 13.46. Halozyme Therapeutics, Inc. (NASDAQ:HALO) showed a weekly performance of -2.56%.

Alliance One International, Inc. (NYSE:AOI) shares remains unchanged in last trading session and ended the day at $1.29. AOI Gross Margin is 11.10% and its return on assets is -1.30%. Alliance One International, Inc. (NYSE:AOI) quarterly performance is -35.18%.